Group 1 - The core point of the article is that Lanfeng Biochemical (SZ 002513) held its 28th meeting of the 7th board of directors on October 24, 2025, via telecommunication, where it reviewed the proposal for the third extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, Lanfeng Biochemical's revenue composition was 77.39% from photovoltaic products and 22.61% from pesticides [1] - As of the time of reporting, Lanfeng Biochemical had a market capitalization of 3.1 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year, highlighting the hot secondary market in biomedicine [1] - A dialogue with Lu Gang, a partner at Chuangdong Investment, indicates that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]
蓝丰生化:10月24日召开董事会会议